Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

• Published in: Alzheimer's research & therapy Vol. 10; no. 1; pp. 113 - 6
• Main Authors: Sánchez-Valle, Raquel, Heslegrave, Amanda, Foiani, Martha S., Bosch, Beatriz, Antonell, Anna, Balasa, Mircea, Lladó, Albert, Zetterberg, Henrik, Fox, Nick C.
• Format: Journal Article
• Language: English
• Published: London BioMed Central 03.11.2018; BioMed Central Ltd; BMC
• Subjects: Alzheimer's disease; Amyotrophic lateral sclerosis; association; biomarker; Biomarkers; Biomedical and Life Sciences; Biomedicine; Care and treatment; chain; Cytoplasmic filaments; Dementia; Familial Alzheimer's disease; frontotemporal dementia; Geriatric Psychiatry; Geriatrics/Gerontology; Immunoassay; Light; Multiple sclerosis; Mutation; Neurodegeneration; Neurofilament light; Neurologi; Neurology; Neurosciences; Neurosciences & Neurology; Presenilin 1; Prevention; protein; Quality control; trials; Biomarkers; Neurofilament light; Alzheimer’s disease; Presenilin 1; Familial Alzheimer’s disease
• ISSN: 1758-9193; 1758-9193
• DOI: 10.1186/s13195-018-0439-y

Background Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups. Methods Serum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests. Results Forty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho = 0.75, p  < 0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho = 0.70, p  < 0.001) and cognitive (rho = −0.77, p  < 0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p  < 0.001). Serum NfL concentration was higher in SMC than in AMC and CTR. Conclusions Serum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.